Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Urinary endothelin in glomerulonephritis patients with normal renal function

D Roccatello1, R Mosso, M Ferro

  • 1Istituto di Nefro-Urologia, Università di Torino, Italy.

Clinical Nephrology
|June 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of life measures in Systemic Lupus Erythematosus: A systematic review.

Reumatismo·2022
Same author

Immunolocalization of hydrophobin HYDPt-1 from the ectomycorrhizal basidiomycete Pisolithus tinctorius during colonization of Eucalyptus globulus roots.

The New phytologist·2021
Same author

Multimodal MRI Longitudinal Assessment of White and Gray Matter in Different SPG Types of Hereditary Spastic Paraparesis.

Frontiers in neuroscience·2020
Same author

Formulation and Clinical Evaluation of Sodium Benzoate Oral Solution for the Treatment of Urea Cycle Disorders in Pediatric Patients.

AAPS PharmSciTech·2020
Same author

Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score.

Seminars in arthritis and rheumatism·2020
Same author

Filling the gap in antiphospholipid syndrome diagnosis: a patient's story.

Lupus·2020

This study found elevated urinary endothelin-1 (ET1) and reduced cyclic GMP (cGMP) in glomerulonephritis patients, indicating an imbalance favoring vasoconstriction. This imbalance may contribute to kidney damage, particularly in IgA nephropathy.

Area of Science:

  • Nephrology
  • Vascular Biology
  • Biochemistry

Background:

  • Endothelin-1 (ET1) is a vasoconstrictor peptide implicated in glomerulosclerosis.
  • Nitric oxide (NO), via cyclic GMP (cGMP), counteracts ET1's effects on mesangial cells.
  • The balance between ET1 and NO/cGMP is crucial in kidney function.

Purpose of the Study:

  • To investigate urinary levels of ET1 and cGMP in patients with biopsy-proven glomerulonephritis (GN).
  • To assess the relationship between ET1 and cGMP as potential markers of disease activity and renal function.
  • To evaluate the ET1/cGMP ratio as an index of the balance between vasoconstrictor and vasorelaxing factors in GN.

Main Methods:

  • Measurement of urinary ET1 and cGMP levels in 58 GN patients (IgA nephropathy, non-IgA mesangial GN, membranous GN) and normal controls.

Related Experiment Videos

  • Analysis of ET1 and cGMP levels in relation to renal function and specific GN subtypes.
  • Calculation of the urinary ET/cGMP ratio to assess the vasoconstrictor/vasorelaxing factor balance.

    • Main Results:

    • Significantly higher urinary ET1 levels were observed in most GN patient groups compared to controls.
    • Urinary cGMP levels were lower in IgA nephropathy patients with renal failure compared to those with normal renal function.
    • The urinary ET/cGMP ratio was elevated in IgA nephropathy patients, suggesting a pro-vasoconstrictive state.

    Conclusions:

    • Hyperexcretion of ET1 is present in various forms of mesangial proliferative GN.
    • An imbalanced ET1/cGMP ratio, particularly in IgA nephropathy with renal impairment, indicates insufficient counter-regulation by NO.
    • This imbalance may contribute to the progression of glomerular damage in GN.